TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01651169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methylphenidate tablets and Inter-stimulus Intervals (ISI)
Description: We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methylphenidate tablets and Inter-stimulus Intervals (ISI)
Description: We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity.
Study: NCT01749852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich Dark chocolate
Description: Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dark chocolate
Description: Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
Study: NCT02846064

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autograft of cryopreserved ovarian tissue
Description: Orthotopic transplantation
Study: NCT01913977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min
Description: Abylcap settings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min
Description: Abylcap settings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min
Description: Abylcap settings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min
Description: Abylcap settings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min
Description: Abylcap settings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min
Description: Abylcap settings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min
Description: Abylcap settings
Study: NCT01984567

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Description: Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
Study: NCT02330172

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of neostigmine or sugammadex
Description: At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected.
Study: NCT01984567

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Daily consumption of 3 placebo capsules
Study: NCT01146977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HDAC chemotherapy
Description: If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous HCT
Description: After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue.
Study: NCT02322086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Rose Bengal, 0.005%
Description: Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
Study: NCT00692549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study: NCT00511186

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIAP
Description: AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
Study: NCT01809899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced consent procedure
Description: Enhanced consent entails a more detailed consent procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consent as Usual
Description: Routine informed consent procedures
Study: NCT03201900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Oral tablet
Study: NCT02790775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF in quadrant 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF in quadrant 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF in quadrant 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF in quadrant 4
Study: NCT00133055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help treatment booklet and telephone support
Description: The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care by a family physician
Description: Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
Study: NCT02875002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volasertib
Description: Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m\^2, is schedule to increase to 100mg/m\^2, and be administered on days 1 and 8 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m\^2 , is scheduled to increase to 1000 mg/m\^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
Study: NCT02927015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Majesty potato chips
Description: Purple Majesty potato chips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mountain Rose potato chips
Description: Mountain Rose potato chips
Study: NCT00943501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
Study: NCT02171832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL, high dose
Study: NCT02844036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous angioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right heart catheterization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A six-minute walking test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional respiratory investigations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary tomography or pulmonary angiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological parameters
Study: NCT01520519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg (3 \* 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
Study: NCT03992677

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01447641

Intervention type: OTHER
Intervention: Polysomnography
Description: Overnight physiological recording of sleep

Intervention type: OTHER
Intervention: Actigraphy
Description: Wristwatch activity to measure basic rest activity cycle and sleep efficiency
Study: NCT00719394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI 136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01516294

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iray
Description: The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
Study: NCT02927015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White potato chips
Description: White potato chips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crackers
Description: Crackers
Study: NCT03848884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence monitoring and education
Description: Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
Study: NCT03231969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 0.2%
Description: 1 drop in each eye at 3 separate times during a 25 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 0.4%
Description: 1 drop in each eye at 3 separate times during a 25 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 0.6%
Description: 1 drop in each eye at 3 separate times during a 25 day period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bilastine 0%
Description: 1 drop in each eye at 3 separate times during a 25 day period.
Study: NCT01434745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Lactose will be administered in a capsule formula.
Study: NCT01772563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volasertib
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: capsules
Study: NCT03630263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw Corn Starch
Description: Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Raw Corn Starch
Description: 200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
Study: NCT05531071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback electrical stimulation
Description: treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with biofeedback electrical stimulation
Description: treated with acupuncture combined with biofeedback electrical stimulation.
Study: NCT02250690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group - tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group (tDCS sham)
Study: NCT03003806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical guided recommendation
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
Study: NCT04380428

Intervention type: OTHER
Intervention: No Intervention. Observational study.
Description: No Intervention. Observational study.
Study: NCT00519545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: Data collection on physiological biomarkers
Study: NCT01322009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid and N-acetyl cysteine
Description: After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
Study: NCT01408810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
Study: NCT01265004

Intervention type: PROCEDURE
Intervention: Stitches
Description: Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching

Intervention type: PROCEDURE
Intervention: Fibrin-glue
Description: Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
Study: NCT00074295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX lung cancer vaccine
Description: 6-7 injections per week in rotating locations for five weeks
Study: NCT02493465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
Study: NCT01196819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firehawk
Description: Implantation of Firehawk drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V
Description: Implantation of Xience V drug eluting stent
Study: NCT01265004

Intervention type: PROCEDURE
Intervention: Stitches and Fibrin-glue
Description: Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
Study: NCT03630133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept System Ablation
Description: Radiofrequency ablation using Intracept System
Study: NCT02708030

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAD
Description: The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
Study: NCT04394195

Intervention type: OTHER
Intervention: measurement of circulating sFlt1 concentration
Description: blood circulating sFlt1 concentration will be determined
Study: NCT02708030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGIT
Description: The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
Study: NCT03945643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50mg administration of sildenafil, one time, one hour prior to measurements.
Study: NCT02034760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy Resistance Training
Description: Supervised Heavy Resistance Training three times weekly for 52 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Intensity Training
Description: Home-based Light Intensity Training three-five times weekly for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Whey
Description: Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Collagen
Description: Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate
Description: Two daily 30g carbohydrate supplementations for 52 weeks.
Study: NCT03488602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F-SPS+UC
Description: Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EUC
Description: Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care.
Study: NCT05589402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Cream 5%
Description: Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation Movement Training
Description: reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
Study: NCT03309345

Intervention type: OTHER
Intervention: No intervention
Description: No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake

Intervention type: OTHER
Intervention: No intervention
Description: No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
Study: NCT02981732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill